“No” is a word they’ve heard too often.

Alexion is a global biopharmaceutical company focused on serving patients with severe and life-threatening rare diseases. Patients with these devastating diseases often have no effective treatment options, and they and their families suffer with little hope. Our goal is to develop and deliver therapies that will dramatically transform their lives.

From Our Leadership

As we fulfil our mission of serving patients with severe and life-threatening rare diseases, Alexion has built its European presence to meet the needs of patients locally. Today, our European operations serve patients in more than 30 countries. In addition, several of Alexion’s key global functions are based in Europe, including our EMEA headquarters in Switzerland and our global supply chain and quality operations in Ireland. We also have a global government affairs team in Brussels, a new research and development centre in Paris, and country operations throughout the region. Alexion’s talented and driven employees are dedicated to providing life-transforming treatments to patients with severe and life-threatening rare diseases for which there are few, if any, effective treatment options. We invite you to learn more about what we do.

— Christophe Bourdon
Senior Vice President, EMEA




Alexion Inaugurates New EMEA Headquarters in Zurich

On November 19, 2015, Alexion proudly inaugurated the new regional headquarters for Europe, Middle East and Africa in Zurich. We dedicate our office and our work to patients and their families living with rare and devastating diseases. We are committed to delivering life-transforming therapies to patients in need every day. The opening ceremony was attended by representatives from the business communities as well as members of the local life science cluster and political representatives.
Read the press release.


European Commission Approves Strensiq® and Kanuma®

The European Commission has approved Kanuma® (sebelipase alfa) for long-term enzyme replacement therapy in patients of all ages with lysosomal acid lipase deficiency (LAL-D), and Strensiq® (asfotase alfa) for long-term enzyme replacement therapy in patients with paediatric-onset hypophosphatasia (HPP) to treat the bone manifestations of the disease. Both Kanuma and Strensiq are the first therapies approved in the EU for the treatment of these life-threatening, ultra-rare metabolic disorders. Read the Kanuma press release and the Strensiq press release. For more information, please refer to the full Summary of Product Characteristics (SmPC) for Kanuma and for Strensiq.



EMEA Headquarters
Alexion Pharma GmbH

Giessh├╝belstrasse 30
8045 Z├╝rich, Switzerland
  • +41 44  457 40 00
  • +41 44 457 40 01